Latest Leadership News

Energy One Limited announces CEO Shaun Ankers will retire at the end of 2026, initiating an international search for his successor to sustain the company’s growth momentum.

Integrated Research reports a softer FY25 with declines in contract value and earnings, yet steady underlying revenue and promising AI-driven product launches signal a strategic pivot.

PIES Holding Co and Activeport Group have launched a strategic joint venture to integrate AI-driven low-code/no-code tools with advanced network orchestration software, aiming to transform telecommunications and data centre operations globally.

betr Entertainment has unveiled an all-scrip takeover bid for PointsBet, offering shareholders 3.81 betr shares per PointsBet share, valuing the offer above a competing cash bid and promising significant cost synergies.

Rapid Critical Metals has completed its capital consolidation and placement, reshaping its issued capital structure with shareholder approval.

Imugene Limited has launched a $37.5 million equity raising through a Placement and Share Purchase Plan, offering new shares and options to fund its pivotal azer-cel clinical program. The raise includes attaching and piggyback options, subject to shareholder approval, aiming to bolster the company’s immuno-oncology pipeline.

Imugene Limited has launched a A$37.5 million capital raising to advance its promising off-the-shelf CAR T therapy, azer-cel, following encouraging Phase 1b data showing a 75% overall response rate in lymphoma patients.

Hawsons Iron Limited has successfully raised $1.91 million through an oversubscribed Share Purchase Plan and a targeted Placement, positioning the company to fast-track key project studies and environmental assessments.

ImpediMed has doubled its US unit sales in Q4 FY25, achieving a record total contract value and securing an additional $5 million tranche under its growth capital facility.

Close the Loop Limited announces a strategic leadership overhaul with new CEOs appointed for North America and Australia, alongside a streamlined operational focus on three core business units.

Prescient Therapeutics has initiated its first US clinical site for the PTX-100 Phase 2a trial targeting Cutaneous T-Cell Lymphoma, marking a key milestone in expanding patient recruitment beyond Australia.

Dalaroo Metals has raised $1 million through a strategic placement supported by cornerstone investors including local partners in Cote d’Ivoire, while announcing the resignation of its CEO. The funds will accelerate exploration across multiple regions and support new project evaluations.